An insulin analog is a man-made substance resembling insulin in which the molecular structure has been altered for a more desirable effect.
Insulin is a hormone, or chemical messenger that is released into the bloodstream to be transported throughout the body. Most hormones, including insulin, are proteins, which means that they are made up of molecules called amino acids. About 20 common varieties of amino acids exist, and the sequence in which they are bound together to form a protein molecule determines both the structure and function of the protein. The human insulin molecule consists of two chains of amino acids, called the A chain and the B chain, which are made up of 21 specific amino acid molecules and 30 specific amino acid molecules, respectively.
In insulin analogs, however, different amino acids are added or substituted at certain positions along the A and B chains. These changes, while altering insulin action times, do not hinder the molecules’ ability to control blood glucose levels in the body. (In this way, insulin analogs may be compared to beef and pork insulin, which differ from human insulin by three amino acids and one amino acid, respectively. These animal insulins were widely used before the advent of the recombinant DNA technology that is now used to manufacture human insulin and insulin analogs.)
One rapid-acting insulin analog is insulin lispro, which is marketed by Eli Lilly and Company as Humalog and became commercially available in 1996. The structure of the insulin lispro molecule is identical to that of human insulin except that the amino acids at two positions on the B chain, B28 and B29, are reversed. This causes the molecules of insulin to disassociate from one another more rapidly after injection, leading to much faster absorption into the bloodstream. As a result, insulin lispro starts acting much more quickly than Regular insulin — within 15 minutes, compared to Regular’s 30–60 minutes — and lasts for a shorter amount of time — three to four hours, compared to Regular’s six to 10 hours. Because of its fast action, insulin lispro should be taken within 15 minutes of eating, while Regular should be taken 30–45 minutes before meals to allow for its slower action. Ideally, insulin taken to “cover” a meal should be reaching peak effectiveness as blood glucose level is peaking. For most people, insulin lispro’s faster action time makes it more convenient than Regular, and studies have shown that blood glucose levels two hours after meals are significantly lower in people who use mealtime insulin lispro as compared with Regular insulin.
Another rapid-acting insulin analog called insulin aspart (marketed by Novo Nordisk as NovoLog) was approved for marketing by the US Food and Drug Administration (FDA) in 2000. In insulin aspart, the amino acid aspartic acid replaces the amino acid proline at position B28. A study published in the journal Diabetes Care in 2003 found no difference between insulin aspart and insulin lispro in terms of action time and effectiveness.
A third rapid-acting insulin analog called insulin glulisine (marketed by Sanofi-Aventis as Apidra) was approved by the FDA in 2004 and became available to consumers in 2006.
In addition to being used for mealtime injections, rapid-acting insulin analogs are also used in insulin pumps. Indeed, the majority of pump users now use either lispro or aspart (rather than Regular). Not only do these analogs work well for mealtime boluses, but they also adjust blood glucose levels rapidly when basal infusion rates are changed. However, any interruption in insulin delivery (because of pump malfunction, for example) can rapidly lead to high blood glucose since the rapid-acting insulin analogs are quickly cleared from the bloodstream.
Also in 2000, the FDA granted marketing approval for a long-acting insulin analog called insulin glargine (brand name Lantus), manufactured by Aventis Pharmaceuticals. In insulin glargine, two molecules of the amino acid arginine are added to one end of the B chain, and one molecule of glycine is substituted for asparagine at position A21. The intermediate-acting insulin NPH is absorbed somewhat unevenly into the bloodstream and has a pronounced “peak” in its activity level. Insulin glargine, however, because of its altered structure, is released very slowly and evenly into the bloodstream. Since its effects last nearly 24 hours with little variability and no peak action level, insulin glargine could be an ideal basal, or long-acting, insulin. A number of studies have compared the use of insulin glargine with that of the widely used NPH. They showed that regimens using insulin glargine offered blood glucose control that was at least as good as and sometimes better than that seen with NPH, and produced fewer episodes of hypoglycemia and less weight gain.
Researchers and manufacturers continue to look for more effective basal insulin analogs. In 2005, a new basal insulin analog called insulin detemir, marketed by Novo Nordisk as Levemir, was approved by the FDA. In insulin detemir, the amino acid threonine is removed from position B30 and a fatty acid is chemically linked to the amino acid lysine at position B29. These changes cause insulin detemir to bind readily to albumin, a protein found in the body, and dissociate slowly, thus prolonging its effect. Insulin detemir lasts an average of 14 hours.
A contributing editor at Diabetes Self-Management, Dinsmoor is an award-winning medical journalist who has written hundreds of articles on health and medicine, including dozens related to diabetes.
Learn more about Robert Dinsmoor:
Source URL: https://www.diabetesselfmanagement.com/diabetes-resources/definitions/insulin-analog/
Disclaimer Statements: Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information provided on this Web site should not be construed as medical instruction. Consult appropriate health-care professionals before taking action based on this information.
Copyright ©2021 Diabetes Self-Management unless otherwise noted.